

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Michael Anthony Cawthorne et al. Art Unit : 1653  
 Serial No. : 09/423,683 Examiner : A. Mohamed  
 Filed : November 10, 1999  
 Title : METHOD AND COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND OTHER CONDITIONS

Box Sequence  
 Commissioner for Patents  
 Washington, D.C. 20231



RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE AND/OR AMINO ACID SEQUENCES

In response to the communication dated January 3, 2001 (copy enclosed), applicant respectfully argues that the instant application, as is, complies with the rules under 37 C.F.R. §1.821-1.825. In accordance with 37 C.F.R. §1.822(b), the sequence disclosures on page 12 and also in the claims of the instant application contain one or more D-amino acid and are therefore excluded. Applicant submits that no Sequence Listing is required.

Respectfully submitted,

Date: 3-2-01

J. Rocky Tsao  
 J. Rocky Tsao  
 Reg. No. 34,053

Fish & Richardson P.C.  
 225 Franklin Street  
 Boston, MA 02110-2804  
 Telephone: (617) 542-5070  
 Facsimile: (617) 542-8906

20203722.doc

RECEIVED  
 MAR 09 2001  
 TECH CENTER 1600/2900

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

March 2, 2001  
 Date of Deposit  
J. H. Payne  
 Signature  
Jennifer H. Payne  
 Typed or Printed Name of Person Signing Certificate

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216 or (703) 308-2923
- For CRF Submission Help, call (703) 308-4212
- For PatentIn software Program Support:
  - HELP DESK: (703) 739-8559, ext 508, M-F, 8 AM to 5 PM EST except holidays
  - Email: [PATIN21HELP@uspto.gov](mailto:PATIN21HELP@uspto.gov)
  - To purchase PatentIn software: (703) 308-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**

MAR 05 2001

PATENT TRADEMARK OFFICE

RECEIVED  
TECH CENTER 1200  
MAR 09 2001